FluoretiQ, which is part of the Deepbridge Life Sciences EIS portfolio, as of February 21st 2022, has announced the completion of a £1.1 million, pre-series A investment. The funding round was led by Deepbridge Capital, with significant participation from MAINStream, OION, SAIC and existing investors. 

This investment will enable the FluoretiQ team to produce trial units of their first NANOPLEX™ product, a 15-minute UTI (Urinary Tract Infection) diagnostic device. 

Dr. Savvas Neophytou, Partner & Head of Life Sciences, Deepbridge Capital commented on the successful round closure: 

“FluoretiQ perfectly represents the type of highly innovative and growth-focused companies Deepbridge Capital is committed to supporting within the sector-specific Deepbridge Life Sciences EIS fund; a great example of the importance of the Enterprise Investment Scheme, Neciah has built a great team, eager to take on the significant challenge this market demands, and we are pleased to be working with them on this next exciting stage of their journey.” 

FluoretiQ Ltd was founded at the Quantum Technology Enterprise Centre (QTEC) in Bristol, with the vision to revolutionise the way bacteria is identified. 

The innovation is designed to be a quick and easy bacteria diagnostic test which uses innovative probes and a powerful fluorescence sensor to detect and identify bacteria in physiological samples. 

FluoretiQ CEO, Dr. Neciah Dorh commented: 

“These funds will enable us to build cutting-edge, rapid diagnostic products that enable true antibiotic stewardship. We’re so fortunate to have a growing list of committed and visionary investors.” 

Click here to find out more. (By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites).